ArticleThe Korean journal of internal medicine2018
Metabolic syndrome: prevalence and risk factors in Korean gout patients.
Article in The Korean journal of internal medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 42 citations in OpenAlex.
- Epidemiological trends and burden of gout in China and the European Union: a GBD 2023 and Mendelian randomization study.Clinical rheumatology · 2026Article
- [Association of metabolic syndrome and its components with gout: an analysis based on a large-scale health survey database].Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2026Article
- Gout: global epidemiology, risk factors, comorbidities and complications: a narrative review.BMC musculoskeletal disorders · 2024Review
- The associations of insulin resistance, obesity, and lifestyle with the risk of developing hyperuricaemia in adolescents.BMC endocrine disorders · 2024Article
- Gout comorbidities: results from the Korean National Health and Nutrition Examination Survey.Advances in rheumatology (London, England) · 2024Article
- Managing Gout in Patients with Metabolic Syndrome.Drugs & aging · 2024Review
- Polymorphism rs3733591 of theFrontiers in genetics · 2024Article
- Epidemiology and treatment-related concerns of gout and hyperuricemia in Korean.Journal of rheumatic diseases · 2023Review
- The Risk of BPPV, Meniere's Disease, and Vestibular Neuronitis in Patients with Gout: A Longitudinal Follow-Up Study Using a National Health Screening Cohort.Journal of clinical medicine · 2022Article
- Risk factors of urinary calculi in men with gout.Clinical rheumatology · 2022Article
- Association between Gout and Dyslipidemia: A Nested Case-Control Study Using a National Health Screening Cohort.Journal of personalized medicine · 2022Article
- Increased risk of incident gout in young men with metabolic syndrome: A nationwide population-based cohort study of 3.5 million men.Frontiers in medicine · 2022Article
- Simple metabolic markers associated with tophaceous gout.Clinical rheumatology · 2021Article
- A global overview of genetically interpretable multimorbidities among common diseases in the UK Biobank.Genome medicine · 2021Article
- Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors.Nature reviews. Rheumatology · 2020Review
- Effects of Urate-Lowering Therapy on Risk of Hyperlipidemia in Gout by a Population-Based Cohort Study and onMediators of inflammation · 2020Article
- Type 2 Diabetes Mellitus, Insulin Resistance, and Vitamin D.Current diabetes reports · 2019Review
- Clinical characteristics of patients under 40 years old with early-onset hyperuricaemia: a retrospective monocentric study in China.BMJ open · 2019Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Aims: We performed this study to investigate associations between metabolic syndrome, chronic kidney disease (CKD), and gout.
methodsWe reviewed the medical records of 151 patients with gout at the Department of Rheumatology in Korea University Ansan Hospital. The following measures were examined: waist circumference, blood pressure, alcohol consumption, and levels of triglyceride, high density lipoprotein cholesterol, fasting serum glucose, serum uric acid (SUA), creatinine, insulin, and C-peptide. We assessed metabolic syndrome by the homeostasis model assessment of insulin resistance (HOMA-IR) index and renal function by the Modification of Diet in Renal Disease equation; patients were classified according to World Health Organization Asia-Pacific obesity criteria.
resultsThe prevalence of metabolic syndrome in gout patients (50.8%) was higher than in non-gout patients. The mean SUA level was significantly higher in gout patients with metabolic syndrome (9.13 ± 3.15 mg/dL) than in gout patients without metabolic syndrome (8.14 ± 2.07 mg/dL). The mean SUA level was also significantly higher in patients with gout and CKD (9.55 ± 2.86 mg/dL) than in patients with gout but no CKD (7.74 ± 2.27 mg/dL). In gout patients, HOMA-IR was positively correlated with waist circumference (r = 0.409, p = 0.001). Conclusions: The prevalence of metabolic syndrome in patients with gout was 50.8%, which is higher than the prevalence in the general Korean population. Hyperuricemia in gout patients was correlated with metabolic syndrome and CKD. Insulin resistance may provide clues to better understand the relationship between metabolic syndrome, CKD, and gout.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.